Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care
about
Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewThe treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patientsAddition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.Primary mediastinal large B-cell lymphoma.Primary mediastinal lymphoma: diagnosis and treatment options.Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphomaPrimary Mediastinal Large B-Cell Lymphoma during Pregnancy.Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy.Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis.Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: ReThe immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis.PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.Assessing the effectiveness of a Grand Rounds CME activity for health-care professionals.Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients.A "PET" topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end.Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
P2860
Q26769596-464C6055-5EDB-4337-890D-13C46E82B4A0Q33568389-2510FC3E-15ED-4B31-BDCB-4CE409D86636Q33716674-06161B51-6E23-429D-91ED-D2BAF347ED4EQ34266819-FC75263E-F4BD-43AA-A779-FA45C11EE514Q34455499-F87BC3F3-4318-427E-8471-03E02595946AQ34649109-FC8A2F53-CCBA-4BD8-A8AC-415306A98292Q35032285-D77CCA77-81D4-4D9E-BC1E-0F73D13BE639Q35564769-A64E2FA1-F7F1-4BAC-8733-28AFD29510A7Q36057764-A527CE37-11F8-4C0D-8B96-C310AE471B88Q36334900-039F1923-A267-4929-B05D-99058B4D3684Q36413484-6E9FC820-4318-4DEC-A950-CF0F4DFB1314Q37274345-EE0D876F-F275-434E-B2FE-9E0E62BD3AF4Q37327973-9B73E4AF-0F42-4D24-852A-7B47453F5E36Q38011619-87A87E6C-3F6E-4EA0-8A47-3FD5EAE74350Q38203924-8BFB9DD8-6E4A-4A04-A16F-AECEC998002AQ39156320-07C21879-DE0E-46CE-93DF-8BFD9D37F865Q40375360-14516DF1-4EB0-4E27-AA74-49AE2B5A1B0CQ40649778-EBF57B45-46AA-4D1B-94DA-6CC3A323CD25Q40812131-551960AE-A752-4C54-AA37-719529E2504CQ41485704-52770CDE-0D82-4CEA-AE30-49AFE748E8E9Q43438554-89B9EE85-2D70-47F3-B2F6-58F3C60B0EF1Q43930995-94928961-3ADD-4DE9-9A3A-76F1E0DEDD13Q44777053-1494404D-354C-486B-B780-848FC06A029BQ46258281-D6398E53-1F5F-4620-A21F-99CE29967AFFQ48371974-18CB97B1-2BC6-4C30-8495-5416F57FA74AQ53049216-05E8C3FC-0561-44E9-85DF-FBF3ED5CBF8AQ53063133-5828BBE0-6D31-4479-884A-F73E18816C4BQ54132017-72A4EB58-8DD7-4ED9-89FF-96377A0E10CFQ56516736-EF2D45AB-CE42-4C1E-9FC1-9DD7D297A3A5
P2860
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@ast
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@en
type
label
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@ast
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@en
prefLabel
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@ast
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@en
P2093
P2860
P1433
P1476
Rituximab, cyclophosphamide, d ...... the emerging standard of care
@en
P2093
Alexandra Zorbala
Andreas Katsigiannis
Christina Kalpadakis
Christos Poziopoulos
Effimia Vrakidou
Evagelia M Dimitriadou
Evangelos Terpos
Gerassimos A Pangalis
John Dervenoulas
John Meletis
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0275
P577
2012-01-26T00:00:00Z